Search Results

You are looking at 1 - 10 of 72 items for :

  • Refine by Access: All x
Clear All
Full access

William J. Catalona and Stacy Loeb

screening based exclusively upon the absolute PSA value, given increasing evidence showing a potential role for PSA kinetics in predicting CaP risk and aggressiveness. Carter et al. 27 reported that PSA levels had a nonsignificant increase over time in

Full access

Stacy Loeb and H. Ballentine Carter

cancer. Conversely, other studies have failed to show an “important” relationship between PSAV and prostate cancer-related outcomes. For example, Vickers et al 16 performed a comprehensive systematic review of studies on PSA kinetics published before

Full access

M. Zach Koontz, Brendan M. Visser, and Pamela L. Kunz

A 36-year-old woman presented to the emergency department with black stools and syncope. Her hemoglobin was 7.0 and her red blood cells were microcytic. Upper endoscopy did not identify a clear source of bleeding, but a bulge in the third portion of the duodenum was noted. A CT scan showed a large extraintestinal mass, and follow-up esophagogastroduodenoscopy/endoscopic ultrasound with biopsy revealed a spindle cell neoplasm, consistent with gastrointestinal stromal tumor (GIST). Because of the size of the lesion and association with the superior mesenteric vein and common bile duct, she was referred to medical oncology for consideration of neoadjuvant imatinib. Neoadjuvant tyrosine kinase inhibitor therapy for GISTs is emerging as a viable treatment strategy for borderline resectable tumors, although the dose, duration, and optimal imaging modalities have not been clearly established. Recent pathologic and radiographic data have provided insight into the mechanism and kinetics of this approach. This case report presents a patient for whom surgery was facilitated using neoadjuvant imatinib.

Full access

David C. Dale

and monocytes . Blood 2008 ; 112 : 935 – 945 . 3 Cartwright GE Athens JW Wintrobe MM . The kinetics of granulopoiesis in normal man . Blood 1964 ; 24 : 780 – 803 . 4 Dancey JT Deubelbeiss KA Harker LA Finch CA . Neutrophil

Full access

David D. Buethe and Julio Pow-Sang

velocity. Characteristics of Cancer Progression/Reclassification Value of PSA Kinetics Although most current large AS trials include PSA kinetics as part of the reclassification criteria ( Table 3 ), in 2009, Vickers et al 61 performed

Full access

Ravi A. Madan, Thomas Schwaab, and James L. Gulley

-Based Therapies May Alter Tumor Growth Patterns This alteration in tumor growth kinetics was initially suggested by a retrospective analysis of 5 NCI trials in mCRPC over the past decade, 4 involving cytoreductive therapy and 1 involving the vaccine PSA

Full access

Charise Gleason, Ajay Nooka, and Sagar Lonial

) neurotoxicity: enhancement by protein-deficient diet . J Appl Toxicol 2004 ; 24 : 497 – 500 . 16 Lonial S Waller EK Richardson PG . Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Full access

Andrew J. Vickers

different ways, either in terms of velocity or doubling time, and with different rules regarding which PSAs are included and how PSA kinetics are calculated. Results showed that, for many definitions, PSA velocity cannot be calculated for a significant

Full access

Pamela S. Becker

than 10%. 65 The kinetics of mobilization are also variable, and some reports have shown the tumor cells to be mobilized with the same kinetics as the hematopoietic progenitrs, and others have reported that there are different peaks of mobilization

Full access

Simon D. Fung-Kee-Fung, Sima P. Porten, Maxwell V. Meng, and Michael Kuettel

surveillance biopsy reflecting that enrollment criteria were no longer met (upgrade to Gleason score >6, or >2 cores with cancer, or >50% cancer involvement of any core). 5 Notably, serum PSA concentration and PSA kinetics were not used as triggers for